ORGO Organogenesis Holdings Inc.


$ 5.84 $ 0.52 (10.18 %)    

Friday, 07-Nov-2025 19:51:53 EST
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
$ 5.11
$ 5.66 x 200
$ 6.00 x 502
$ 4.99 - $ 6.20
$ 2.61 - $ 6.71
33,040,226
na
714.52M
$ 1.24
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 correction-organogenesis-hldgs-q3-adj-eps-018-beats-006-estimate-sales-150864m-beat-134100m-estimate

Organogenesis Hldgs (NASDAQ:ORGO) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $...

 organogenesis-holdings-raises-fy2025-net-product-revenue-guidance-from-480000m-510000m-to-500000m-525000m

Organogenesis Holdings (NASDAQ:ORGO) raises FY2025 Net product revenue outlook from $480.000 million-$510.000 million to $500.0...

 organogenesis-hldgs-q3-adj-eps-018-beats-006-estimate-sales-150587m-beat-134100m-estimate

Organogenesis Hldgs (NASDAQ:ORGO) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $...

 why-is-organogenesis-stock-trading-lower-friday

Organogenesis Holdings Inc. (NASDAQ: ORGO) shared topline data on Thursday from the second Phase 3 randomized controlled trial ...

Core News & Articles

Gainers bioAffinity Technologies (NASDAQ: BIAF) stock increased by 71.8% to $5.86 during Friday's pre-market session. The ...

 btig-reiterates-buy-on-organogenesis-holdings-maintains-7-price-target

BTIG analyst Ryan Zimmerman reiterates Organogenesis Holdings (NASDAQ: ORGO) with a Buy and maintains $7 price target.

Core News & Articles

Gainers Galecto (NASDAQ: GLTO) stock rose 21.6% to $5.41 during Thursday's after-market session. The market value of their...

 organogenesis-announces-that-the-second-phase-3-randomized-controlled-trial-of-renu-did-not-achieve-statistical-significance-for-its-primary-endpoint-despite-the-renu-results-demonstrating-a-numerical-improvement-in-baseline-pain-reduction-over-the-first-phase-3-trial

CANTON, Mass., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc.

 cantor-fitzgerald-maintains-overweight-on-organogenesis-holdings-raises-price-target-to-9

Cantor Fitzgerald analyst Ross Osborn maintains Organogenesis Holdings (NASDAQ:ORGO) with a Overweight and raises the price ...

 organogenesis-holdings-narrows-fy2025-sales-guidance-from-48000m-53500m-to-48000m-51000m-vs-47780m-est

Organogenesis Holdings (NASDAQ:ORGO) narrows FY2025 sales outlook from $480.00 million-$535.00 million to $480.00 million-$510....

 organogenesis-hldgs-q2-adj-eps-006-misses-005-estimate-sales-10078m-miss-10117m-estimate

Organogenesis Hldgs (NASDAQ:ORGO) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of...

 cantor-fitzgerald-reiterates-overweight-on-organogenesis-holdings-maintains-7-price-target

Cantor Fitzgerald analyst Ross Osborn reiterates Organogenesis Holdings (NASDAQ:ORGO) with a Overweight and maintains $7 pri...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION